Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to identified patient could be omitted from internal mammary lymph node irradiation by using a clinical-genomic model.

Trial Details

NCT ID
NCT04517266
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • omit of IMI group
  • IMI group
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • • Histologically confirmed invasive breast cancer
  • Underwent radical surgery with either mastectomy or breast conserving surgery and axillary lymph node dissection (ALND)
  • The number of positive lymph node should be 1-3 (N1).
  • Clinical high risk breast cancer (≥2 clinical risk factors)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →